Abstract
The German start-up Modag has raised about $14 million in series A financing to begin testing small-molecule drugs for neurodegenerative diseases in clinical studies. Modag’s lead drug candidate, called anle138b, binds toxic oligomers of α-synuclein, a protein whose aggregation is implicated in Parkinson’s disease. To start, Modag will test the compound in a rare disease called multiple system atrophy, which is similar to Parkinson’s. The company was founded in 2013 by scientists from Ludwig Maximilian University of Munich and the Max Planck Institute for Biophysical Chemistry.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
